Skip to main content

Branded

  • 'Picture This' forums bring diabetes management awareness to public

    PRINCETON, N.J. A few days after it released a report on how awareness and education play an integral role in the prevention, detection and treatment of diabetes, Novo Nordisk is bringing it to the public.

  • Genentech's Herceptin receives FDA approval

    SOUTH SAN FRANCISCO, Calif. The Food and Drug Administration has approved a biotech drug for treating cancer of the stomach and esophageal junction.

     

    Genentech, a subsidiary of Swiss drug maker Roche, announced Wednesday the approval of Herceptin (trastuzumab) as a treatment for cancer of the stomach that includes the HER2 gene and has spread to other parts of the body, when combined with chemotherapy. The drug has long since had approval as a treatment for HER2-positive breast cancer.

     

     

  • Cardiovascular, diabetes risk associated with prostate cancer drug class

    SILVER SPRING, Md. Patients taking a certain class of drugs mostly used for prostate cancer may be at higher risk of heart disease and diabetes, the Food and Drug Administration warned on Wednesday.

     

  • FDA approves BI's Pradaxa

    SILVER SPRING, Md. The Food and Drug Administration approved a drug for preventing strokes and blood clots in patients with abnormal heart rhythm, the agency said Tuesday.

     

    The FDA announced the approval of Pradaxa (dabigatran etexilate) capsules, an anticlotting drug made by Boehringer Ingelheim for patients with atrial fibrillation, a type of abnormal heart rhythm that affects more than 2 million Americans.

     

     

  • FDA declines to approve Bydureon

    INDIANAPOLIS The Food and Drug Administration declined to approve a long-anticipated diabetes drug made by Eli Lilly and two other companies, the companies said Tuesday.

    Lilly, Amylin Pharmaceuticals and Alkermes said the FDA issued them a complete response letter for their application for Bydureon (exenatide), a once-weekly version of the Type 2 diabetes drug Byetta. A complete response letter means that the FDA has completed review of a regulatory application, but issues remain that preclude approval.

     

  • Novo Nordisk looks at ways to raise diabetes awareness in new report

    PRINCETON, N.J. Novo Nordisk is underscoring the importance of diabetes screenings with a new report, the Novo Nordisk BlueSheet.

    The third edition of the drug maker's BlueSheet report examined various ways awareness and education play an integral role in the prevention, detection and treatment of diabetes. It also provides an update on the Diabetes Advocacy Alliance, a coalition that is committed to helping improve diabetes prevention, detection and care by aligning key diabetes stakeholders around diabetes-related policy and legislative efforts.

  • Purdue Pharma supports state Rx monitoring programs

    CHARLESTON, S.C. Drug maker Purdue Pharma has donated $200,000 to the National Association of State Controlled Substances Authorities to address the abuse of prescription drugs, NASCSA said Tuesday.

     

    The grant, presented at the group’s annual conference in Charleston, S.C., is designed to support state prescription drug monitoring programs. The NASCSA will be in charge of distributing the money to state agencies. Purdue is the maker of OxyContin (oxycodone), a commonly abused prescription opioid painkiller.

     

     

  • FDA OKs expanded use of Baraclude

    PRINCETON, N.J. The Food and Drug Administration has approved an additional use for a hepatitis drug.

     

    Bristol-Myers Squibb announced Monday the approval of Baraclude (entecavir) as a treatment for chronic hepatitis B in adults with decompensated liver disease. The drug already is approved for adults with evidence of active viral replication.

     

     

X
This ad will auto-close in 10 seconds